10 Must-Attend E-Cigarette Exhibitions in 2023

Nov.24.2022
10 Must-Attend E-Cigarette Exhibitions in 2023
2FIRSTS held an online event on Nov 24, 2022, discussing the top 10 must-attend exhibitions in 2023 for the e-cigarette industry.

On November 24th, 2022 at 3:00 PM, 2FIRSTS conducted an online live-streamed event with the theme "Ten exhibitions that must be attended in 2023".


Jason, the International Public Relations Manager of 2FIRSTS, presented on the topic of worthwhile exhibitions to attend at the 2023 global electronic cigarette trade show. Drawing from the experience of 2FIRSTS in exhibiting and managing trade shows, he provided valuable insights and recommendations on how to successfully execute these events, accompanied by concrete case studies and a thorough analysis.


During the livestream, Jason mentioned that the new type of tobacco can participate in exhibitions beyond just tobacco and e-cigarette shows. CBD, consumer, and consumer electronics product exhibitions are also potential considerations.


Jason, the International PR Manager of 2FIRSTS, acted as the keynote speaker based on the company's exhibition and management experience for 2022. Image source: 2FIRSTS.


FIRSTS has exclusively curated a list of trade shows worth attending in 2023, with a breakdown of 12 events in the Americas, 23 in Europe, 4 in Asia, 1 in the Middle East, and 1 in Africa. The list includes recommendations and alternatives for attendees to consider. It offers helpful suggestions for those looking for guidance on which events to prioritize.


Image source: Exclusive compilation by 2FIRSTS.


Jason's recommended 10 exhibitions are:


Several trade shows featuring products related to the vaping industry are held around the world each year, including the Lift & Co Expo in the United States and Canada, Total Product Expo in the United States and the Americas, Alternative Product Expo in the United States and the Americas, World Vape Show in the United States, Paraguay, and Dubai, The Vapor Expo UK in the United States, Vapitaly in Italy, Vapitaly Pro in Italy, Intertabac in Germany, and Intertabac in Indonesia and the United States, as well as VapExpo in France, Spain, and the United States.


Trade shows not only serve to increase revenue, but also act as a point of contact for the market and brand, as well as a great opportunity to open up new markets.


During the live broadcast, Jason mentioned that some popular trade shows require bookings up to a year in advance. The preparation work required for hosting a trade show – from designing and constructing booths, to managing logistics and ensuring the venue is suitable – is extensive and time-consuming.


2FIRSTS has extensive and professional experience in organizing joint exhibitions. In 2022, they achieved great success in collaboration with the ECCC exhibition team at the tobacco exhibition in Dortmund, Germany and the electronic cigarette exhibition in Birmingham, UK. They expanded their client resources by over 300 companies at each event, with a client conversion rate of over 10%.


2FIRSTS realized through deep cultivation and exploration of the atomization industry that collaborating with other companies is the most cost-effective way to achieve high returns.


Multiple companies are sharing a single exhibition booth, which facilitates cost-sharing. The booth is bustling with activity and draws a large crowd, while logistics expenses have decreased by 50%. Additionally, without the need for multiple travel expenses like airfare and hotel accommodation, personnel costs have reduced by 80%.


As a result, in 2023, 2FIRSTS will be introducing a choice between two exhibition formats and booth designs. 2FIRSTS will provide services offering joint exhibitions, marketing and promotions, data and reporting, and other additional benefits.


Among them, the collaborative exhibition team has exhibited service equity items, including:


Various companies had their exclusive exhibition booths and showcased their products. Service personnel dedicated to each company provided explanations about their products. The construction and design of these exclusive exhibition booths were carefully planned and executed. These personnel were also readily available to connect companies to potential clients and resources, and facilitated on-site factory inspections for overseas clients, ultimately maximizing sales and promoting business growth.


2FIRSTS aims to facilitate the positive development of the global alternative tobacco industry and become a key value-added service provider in the industry chain, based on a long-term optimistic outlook on the technological and consumer changes in the industry.


If you are interested in collaborating on the 2023 electronic cigarette industry exhibition, please contact 2FIRSTS Business Director Luo Feng or International Public Relations Manager Jason. Contact information is as follows.


Statement


1. This article is intended solely for industry insiders to exchange and explore ideas, and does not contain any brand or product promotion or endorsement. 2. Smoking is harmful to health. This article is not intended for minors to read.


This article is an original creation of 2FIRSTS Technology Co., Ltd. in Shenzhen, and its copyright and usage permission are owned by the company. Any unauthorized copying, reproduction, or other use that infringes on the company's copyright by any individual or organization is strictly prohibited and may result in legal action taken by the company.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia's Therapeutic Goods Administration published a final decision on September 25 to classify 6-methylnicotine as a Schedule 9 prohibited substance under the Poisons Standard, effective October 1, 2026. TGA said the chemical has been reported in e-cigarette liquids sold in Australia and marketed as nicotine-free or nicotine alternatives, while evidence also indicates its use in preparations such as oral pouches. The government originally proposed a Schedule 7 classification but ultimately adopted the stricter Schedule 9 designation, citing acute toxicity, dependence risk, use in unapproved consumer products and misleading marketing.
News
Sep.29 by 2Firsts Perspectives
Imperial Brands Acquires Helwit Owner Yoik Group for SEK 515 Million, More Than Doubling Swedish Nicotine Pouch Share
Imperial Brands Acquires Helwit Owner Yoik Group for SEK 515 Million, More Than Doubling Swedish Nicotine Pouch Share
Imperial Brands has agreed to acquire 100% of Swedish modern oral nicotine company Yoik Group AB for an initial SEK515 million, equivalent to about US$53.9 million, plus a deferred payment linked to performance over the next two years. Yoik owns nicotine pouch brand Helwit, which held about 3.4% of Sweden’s modern oral nicotine market over the past 12 months. Imperial says the acquisition will more than double its existing share of the Swedish market. Helwit is also sold elsewhere in the Nordics, through European online channels and in selected UK retail outlets.
Sep.08
Special Report | Altria Subsidiaries Sue FDA to Vacate 2021 PMTA Rule as Agency Moves to Speed Reviews
Special Report | Altria Subsidiaries Sue FDA to Vacate 2021 PMTA Rule as Agency Moves to Speed Reviews
2Firsts reviewed the original federal court complaint filed by Altria subsidiaries Helix Innovations and NJOY on Sept. 2 challenging FDA’s 2021 PMTA rule. The lawsuit questions whether FDA’s review process complies with the Tobacco Control Act’s 180-day timeline, even as the agency moves to accelerate PMTA reviews and issues more marketing orders. Drawing on the complaint, FDA records, government audits and recent court rulings, 2Firsts examines the legal arguments, supporting evidence and potential implications for the U.S. tobacco review system.
Regulations
Sep.03
Exclusive Analysis | Smoore H1 Revenue Rises 19.9% Amid Growth Concentration, Profit Pressure and Slowing Momentum
Exclusive Analysis | Smoore H1 Revenue Rises 19.9% Amid Growth Concentration, Profit Pressure and Slowing Momentum
Smoore’s first-half 2026 revenue rose 19.9%, but the results revealed growing structural risks beneath the headline growth. Heat-not-burn contributed about 61% of incremental revenue and remains driven largely by one core customer, while traditional vaping markets diverged, own-brand growth slowed and China enterprise revenue declined further. Gross profit and adjusted profit lagged revenue growth, while second-quarter revenue growth slowed to about 1.9%, putting greater focus on the quality, concentration and sustainability of Smoore’s expansion.
Capital Markets
Aug.20
F1 Faces Renewed Pressure Over Tobacco and Nicotine Sponsorships as 67 Groups Target ZYN and VELO Ahead of Madrid Race
F1 Faces Renewed Pressure Over Tobacco and Nicotine Sponsorships as 67 Groups Target ZYN and VELO Ahead of Madrid Race
Ahead of the Formula 1 race in Madrid, 67 Spanish and international public-health, medical and consumer organizations have sent an open letter to F1 President and CEO Stefano Domenicali calling for an end to sponsorships linked to the tobacco and nicotine industry, including nicotine pouches, vaping products and heated tobacco. The letter focuses on Philip Morris International’s ZYN partnership with Ferrari and British American Tobacco’s long-running partnership with McLaren and exposure for VELO. The campaign follows a March letter in which more than 160 organizations worldwide made a similar request to Formula 1.
Sep.10
2Firsts Compliance Solutions Hosts PMTA Briefing on FDA Review Signals After JUUL2 Authorization
2Firsts Compliance Solutions Hosts PMTA Briefing on FDA Review Signals After JUUL2 Authorization
Following recent FDA authorizations for JUUL2 and ZYN ULTRA, 2Firsts Compliance Solutions held an online PMTA briefing on Sept. 4 to examine what the decisions may signal about review efficiency, scientific evidence and U.S. market access. Nearly 30 participants from brands, manufacturers, compliance service providers and investment firms joined the discussion.
2Firsts Events
Sep.06